Menu

Covid-19 Frontline Grand Rounds Enduring Activity: A Light in the Darkness: New Virus-neutralizing Monoclonal Antibodies and Other Point-of-Care Therapies Recently Granted Emergency Use Authorizations for Patients with Covid-19

When:
May 11, 2021 @ 7:00 am – May 11, 2022 @ 8:00 am
2021-05-11T07:00:00-04:00
2022-05-11T08:00:00-04:00

Covid-19 Frontline Grand Rounds Enduring Activity: A Light in the Darkness: New Virus-neutralizing Monoclonal Antibodies and Other Point-of-Care Therapies Recently Granted Emergency Use Authorizations for Patients with Covid-19

VIEW ACTIVITY

PROGRAM CHAIR

Shyam Kottilil, MD, PhD (PROGRAM CHAIR)
Professor of Medicine
Chief, Division of Infectious Diseases
Institute of Human Virology
University of Maryland
Baltimore, MD

PROGRAM OVERVIEW

The COVID-19 FRONTLINE Grand Rounds series provides a comprehensive and up-to-date perspective on the ever-changing management of patients with COVID-19. Each Grand Rounds session features in-depth case studies to encourage retention of the lessons and provide new perspectives on the management of patients during the COVID-19 pandemic. This program will focus on optimizing outcomes for hospitalized and nonhospitalized patients with COVID-19 through the use of novel agents authorized for emergency use.


TARGET AUDIENCE

This CME initiative is designed for HCPs who are involved in the care and treatment of patients with COVID-19 in an outpatient setting, including physicians, NPs, PAs, nurses, pharmacists, and paramedics.


LEARNING OBJECTIVES

Upon the completion of this program, attendees should be able to:

  • Assess the rationale for the use of neutralizing monoclonal antibody therapies in recently diagnosed COVID-19 patients to prevent the development of severe disease
  • Critique the efficacy and safety of new virus-neutralizing monoclonal antibody therapies and other therapies approved for emergency use in all patients who test positive for COVID-19
  • Develop in-clinic infusion capability in order to administer new virus-neutralizing monoclonal antibodies to patients with COVID-19 at the point-of-care

ACCREDITATION STATEMENT

Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. This CME activity was planned and produced in accordance with the ACCME Essentials.


CREDIT DESIGNATION STATEMENT

Med Learning Group designates this online activity for a maximum of 1.0 AMA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the online activity.


NURSING CREDIT INFORMATION

Purpose: This program would be beneficial for nurses involved in the care of patients with Covid-19.
CNE Credits: 1.0 ANCC Contact Hour.


CNE ACCREDITATION STATEMENT

Ultimate Medical Academy/Complete Conference Management (CCM) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. Awarded 1.0 contact hour of continuing nursing education of RNs and APNs.


DISCLOSURE POLICY STATEMENT

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.


DISCLOSURE OF CONFLICTS OF INTEREST

Faculty Member Disclosures
Shyama Kottilil, MD, Ph.D. Discloses that the University of Maryland has received funds to participate in trials, as well he has received research funds paid to the university from Merck Inc, Gilead Sciences and Arbutus Pharmaceuticals. He has also provided contracted research for Regeneron, Eli Lilly, and air Pharmaceuticals, as well as serving on the advisory board for hepatitis b functional cure program at Merck Inc.

CME Content Review
The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.

CNE Content Review
The content of this activity was peer reviewed by a nurse reviewer.
The reviewer of this activity has nothing to disclose.

Staff, Planners, and Managers
The staff, planners, and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:
Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
Christina Gallo, SVP, Educational Development for Med Learning Group, has nothing to disclose.
Diana Tommasi, PharmD, Medical Director for Med Learning Group has nothing to disclose.
Lauren Welch, MA, VP, Accreditation and Outcomes for Med Learning Group, has nothing to disclose.
Marissa Mays-Verman, Program Manager for Med Learning Group, has nothing to disclose.
Russie Allen, Accreditation and Outcomes Coordinator for Med Learning Group, has nothing to disclose.


DISCLOSURE OF UNLABELED USE

Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.

During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.


METHOD OF PARTICIPATION

There are no fees for participating and receiving CME credit for this online activity. To receive CME/CNE credit participants must:

  1. Read the CME/CNE information and faculty disclosures.
  2. Participate in the online activity.
  3. Complete the online post-test and evaluation.

You will receive your certificate as a downloadable file.


DISCLAIMER

Med Learning Group makes every effort to develop CME activities that are science based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision making before applying any information, whether provided here or by others, for any professional use.

For CME questions, please contact Med Learning Group at [email protected].

RELEASE DATE: May 11, 2021

EXPIRATION DATE: May 11, 2022

Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/

AMERICANS WITH DISABILITIES ACT

Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected].

Copyright © 2021 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.

VIEW ACTIVITY

 

Menu

Updates in the Treatment and Prevention of COVID-19​

First Single-Dose COVID-19 Vaccine Authorized for Emergency Use

On February 27, 2021, the US Food and Drug Administration (FDA) authorized a single-dose vaccine for emergency use to prevent COVID-19 in individuals 18 years of age and older. The FDA partly based its decision on data from the phase 3 EMSEMBLE trial, which was conducted in eight countries across three continents and included patients infected with emerging viral variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Data from this study demonstrated that the vaccine was 85% effective in preventing severe disease across all geographic regions studied. The level of protection against moderate and severe COVID-19 was 72% in the United States. The vaccine also provided protection against COVID-19-related hospitalization and death, beginning 28 days after vaccination. The Ad.26.COV2.S vaccine is a recombinant vector vaccine developed by the Janssen Pharmaceutical Companies of Johnson & Johnson that uses a human adenovirus to express the SARS-CoV-2 spike protein.

References:

National Institutes of Health (NIH). Janssen investigational COVID-19 vaccine: interim analysis of phase 3 clinical data released. January 29, 2021. Available at www.nih.gov/news-events/news-releases/janssen-investigational-covid-19-vaccine-interim-analysis-phase-3-clinical-data-released  Accessed 3/2/2021.

Johnson & Johnson COVID-19 vaccine authorized by U.S. FDA for emergency use—first single-shot vaccine in fight against global pandemic. February 27, 2021. Available at www.jnj.com/johnson-johnson-covid-19-vaccine-authorized-by-u-s-fda-for-emergency-usefirst-single-shot-vaccine-in-fight-against-global-pandemic  Accessed 3/2/2021.